Dr. Reddy’s Laboratories has acquired the India trademarks for the Hormone Replacement Therapy (HRT) drugs Progynova® and Cyclo-Progynova® from Mercury Pharma Group Limited for $32.15 million. This strategic acquisition is expected to significantly bolster Dr. Reddy’s gynecology portfolio and mark its entry into the HRT segment in India, drawing investor attention to its shares. Despite a slight dip in share price on Wednesday, the company shows strong technical indicators and a shift in institutional holdings with mutual funds increasing their stake while FPIs reduced theirs.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Dr. Reddy’s Laboratories shares in focus after acquiring India trademarks for two HRT drugs for $32 million
Dr. Reddy’s Laboratories has acquired the India trademarks for the Hormone Replacement Therapy (HRT) drugs Progynova® and Cyclo-Progynova® from Mercury Pharma Group Limited for $32.15 million. This strategic acquisition is expected to significantly bolster Dr. Reddy’s gynecology portfolio and mark its entry into the HRT segment in India, drawing investor attention to its shares. Despite a slight dip in share price on Wednesday, the company shows strong technical indicators and a shift in institutional holdings with mutual funds increasing their stake while FPIs reduced theirs.